Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
APLLTD Stock Chart & Stats
₹930.30
-₹4.90(-0.46%)
At close: 4:00 PM EST
₹930.30
-₹4.90(-0.46%)
Day’s Range― - ―
52-Week Range₹635.30 - ₹1,107.80
Previous CloseN/A
Volume60.71K
Average Volume (3M)9.71K
Market Cap
₹128.94B
Enterprise Value₹142.44B
Total Cash (Recent Filing)₹1.55B
Total Debt (Recent Filing)₹14.89B
Price to Earnings (P/E)31.3
Beta0.94
Next Earnings
May 06, 2026EPS Estimate
8.27Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)8.90
Shares Outstanding196,563,130
10 Day Avg. Volume3,953
30 Day Avg. Volume9,706
Financial Highlights & Ratios
PEG Ratio-5.74
Price to Book (P/B)3.40
Price to Sales (P/S)2.64
P/FCF Ratio-37.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)42.5
Revenue Forecast (FY)₹82.05B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsAlembic's multi-pronged model — domestic branded formulations, regulated-market generics, an in-house API business and contract manufacturing potential — creates durable revenue optionality, lowers single-market dependency, and supports margin and volume stability over the medium term.
Improving Revenue And EBIT MarginsSustained improvements in revenue and EBIT margins alongside strong gross margins indicate structural operational improvements or pricing power. Over 2–6 months this underpins cash generation potential and reinvestment capacity if maintained, supporting competitive positioning and product investments.
Healthy Equity Base And Robust ROEA strong equity ratio and robust ROE provide a capital cushion and signal efficient use of shareholder funds. This durability supports funding of R&D, capacity expansion or M&A without immediate equity dilution, improving financial resilience through business cycles.
Bears Say
Declining Free Cash FlowFalling free cash flow and reduced operating cash conversion constrain the firm's ability to self-fund capex, pay down debt or return cash to shareholders. If elevated capex persists without commensurate revenue uplift, financing needs or margin pressure may increase over the medium term.
Rising LeverageAn increasing debt-to-equity ratio raises interest and refinancing risk, lowering financial flexibility. Over months, higher leverage can restrict strategic moves, increase cost of capital, and amplify downside in slower demand environments, stressing liquidity management.
Net Profit Margin VolatilityVariable net margins suggest inconsistent cost control, pricing pressure or mix shifts. This reduces earnings predictability and complicates budgeting for R&D and commercial investments, making medium-term cash flow and profitability less reliable for stakeholders.
Alembic Pharmaceuticals Limited News
APLLTD FAQ
What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?
Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1107.80 in the past 12 months.
What is Alembic Pharmaceuticals Limited’s market cap?
Alembic Pharmaceuticals Limited’s market cap is ₹128.94B.
When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?
Alembic Pharmaceuticals Limited’s upcoming earnings report date is May 06, 2026 which is in 29 days.
How were Alembic Pharmaceuticals Limited’s earnings last quarter?
Alembic Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹8.9 earnings per share for the quarter, beating the consensus estimate of ₹8.372 by ₹0.528.
Is Alembic Pharmaceuticals Limited overvalued?
According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued.
Does Alembic Pharmaceuticals Limited pay dividends?
Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.28%. See more information on Alembic Pharmaceuticals Limited dividends here
What is Alembic Pharmaceuticals Limited’s EPS estimate?
Alembic Pharmaceuticals Limited’s EPS estimate is 8.27.
How many shares outstanding does Alembic Pharmaceuticals Limited have?
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.
What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?
Alembic Pharmaceuticals Limited reported an EPS of ₹8.9 in its last earnings report, beating expectations of ₹8.372. Following the earnings report the stock price went up 1.409%.
Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:APLLTD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Technical Analysis
GlaxoSmithKline Pharmaceuticals Limited
―
JB Chemicals & Pharmaceuticals Ltd.
―
Jubilant Pharmova Limited
―
Marksans Pharma Limited
―
NATCO Pharma Limited
―